IRIS
CIMADAMORE, Alessia
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 182
EU - Europa 116
AF - Africa 72
AS - Asia 37
SA - Sud America 2
Totale 409
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 182
IT - Italia 88
TG - Togo 67
CN - Cina 12
IE - Irlanda 7
GB - Regno Unito 6
IN - India 6
BD - Bangladesh 4
FI - Finlandia 4
DE - Germania 3
HK - Hong Kong 3
IQ - Iraq 3
NL - Olanda 3
TR - Turchia 3
DZ - Algeria 2
EG - Egitto 2
GR - Grecia 2
KW - Kuwait 2
AE - Emirati Arabi Uniti 1
AR - Argentina 1
CL - Cile 1
CZ - Repubblica Ceca 1
ES - Italia 1
IR - Iran 1
JP - Giappone 1
RU - Federazione Russa 1
SA - Arabia Saudita 1
ZA - Sudafrica 1
Totale 409
Salva come PNG Salva come JPEG
Città #
Lomé 67
Ogden 59
Ashburn 14
Codroipo 13
Milan 8
Dublin 7
Naples 6
New York 6
Orta Nova 6
Lappeenranta 4
Porcia 4
Rome 4
Al Hillah 3
Secaucus 3
Trabzon 3
Aligarh 2
Athens 2
Bari 2
Bengaluru 2
Cavaso del Tomba 2
Dongguan 2
Frankfurt am Main 2
Frosinone 2
Giza 2
Kolkata 2
Kuwait City 2
Magliano in Toscana 2
Oude Meer 2
Padova 2
Perugia 2
Scandicci 2
Seattle 2
Slough 2
Triggiano 2
West Jordan 2
Xi'an 2
Boardman 1
Carpenedolo 1
Chapel Hill 1
Dhaka 1
Fontebuona 1
General Rodriguez 1
Glenwood 1
Groningen 1
Houston 1
Jeddah 1
Liberec 1
Limena 1
London 1
Los Angeles 1
Madrid 1
Miami 1
Nauen 1
Otemachi 1
Penalolen 1
Ronchi dei Legionari 1
Shanghai 1
Shiraz 1
Siena 1
Srimangal 1
St Petersburg 1
Temecula 1
The Dalles 1
Treviolo 1
Udine 1
Wanchai 1
Totale 279
Salva come PNG Salva come JPEG
Nome #
News in the classification of WHO 2022 bladder tumors 46
SIUrO best practice recommendations to optimize BRCA 1/2 gene testing from DNA extracted from bone biopsy in mCRPC patients (BRCA Optimal Bone Biopsy Procedure: BOP) 20
Apalutamide or enzalutamide in castration-sensitive prostate cancer: a number needed to treat analysis 18
Efficacy of Different Bacillus of Calmette-Guérin (BCG) Strains on Recurrence Rates among Intermediate/High-Risk Non-Muscle Invasive Bladder Cancers (NMIBCs): Single-Arm Study Systematic Review, Cumulative and Network Meta-Analysis 16
Atlas of PD-L1 for Pathologists: Indications, Scores, Diagnostic Platforms and Reporting Systems 14
Digital real-time microscopy of ex-vivo tissues: A novel strategy to control surgical accuracy 14
Histopathology of Prostate Cancer and its Precursors 14
How To Report the Minor Component of a High-grade Pattern in Radical Prostatectomy Specimens: Time To Abandon the “Tertiary” Terminology? 13
The pathway of isolated seminal vesicle invasion has a different impact on biochemical recurrence after radical prostatectomy and pelvic lymphadenectomy 11
Frequent Telomerase Reverse Transcriptase Promoter and Fibroblast Growth Factor Receptor 3 Mutations Support the Precursor Nature of Papillary Urothelial Hyperplasia of the Urinary Bladder 10
Follow-up of the Urethra and Management of Urethral Recurrence After Radical Cystectomy: A Systematic Review and Proposal of Management Algorithm by the European Association of Urology-Young Academic Urologists: Urothelial Carcinoma Working Group 10
Tumors of the Urinary System and Male Genital Organs: 2022 World Health Organization Classification and Multidisciplinarity 9
A gender-related dichotomy in bladder cancer 9
Accuracy of the CUETO, EORTC 2016 and EAU 2021 scoring models and risk stratification tables to predict outcomes in high-grade non-muscle-invasive urothelial bladder cancer 9
Phase II study of nivolumab and salvage nivolumab/ipilimumab in treatment-naïve patients with advanced non-clear cell renal cell carcinoma (HCRN GU16-260-Cohort B) 9
Re: George J. Netto, Mahul B. Amin, Eva M. Compérat, et al. Prostate Adenocarcinoma Grade Group 1: Rationale for Retaining a Cancer Label in the 2022 World Health Organization Classification. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.09.015 8
Myoid gonadal stromal tumours are characterised by recurrent chromosome-level copy number gains: molecular assessment of a multi-institutional series 8
Adjuvant and neoadjuvant approaches for urothelial cancer: Updated indications and controversies 8
OUTCOMES OF DIFFERENT PATTERN OF SEMINAL VESICLE INVASION IN PATIENTS TREATED WITH RADICAL PROSTATECTOMY 7
Re: Martha Boone. The Unfettered Urologist. What I Never Had Time to Tell You in a Fifteen Minute Office Visit. New York, NY: Morgan James Publishing; 2023 7
Incorporating Prognostic Biomarkers into Risk Assessment Models and TNM Staging for Prostate Cancer 7
Re: Gillian Vandekerkhove, Werner J. Struss, Matti Annala, et al. Circulating Tumor DNA Abundance and Potential Utility in De Novo Metastatic Prostate Cancer. Eur Urol 2019;75:667–75: How Does Circulating DNA Reach the Blood Stream? 7
An insight on novel molecular pathways in metastatic prostate cancer: A focus on ddr, msi and akt 7
Surgical pathology of cystic renal cell carcinomas: is there an overestimation of malignancy? 7
PARP Inhibitors and Radiometabolic Approaches in Metastatic Castration-Resistant Prostate Cancer: What’s Now, What’s New, and What’s Coming? 7
Re: Timothy D. Jones, Liang Cheng. Histologic Grading of Bladder Tumors: Using Both the 1973 and 2004/2016 World Health Organization Systems in Combination Provides Valuable Information for Establishing Prognostic Risk Groups. Eur Urol 2021;79:489–91 6
Biomarkers of Angiogenesis and Clinical Outcomes to Cabozantinib and Everolimus in Patients with Metastatic Renal Cell Carcinoma from the Phase III METEOR Trial 6
Conceptual Analogies Between Multi-Scale Feeding and Feedback Cycles in Supermassive Black Hole and Cancer Environments 6
The Prostatic Utricle and Endometrioid Prostate Cancer: Similarities, Differences and Challenges 6
Re: Human Chimeric Antigen Receptor Macrophages for Cancer Immunotherapy 6
The most effective but largely ignored target for prostate cancer early detection and intervention 6
Variants and Variations in Epithelial Renal Cell Tumors in Adults: The Pathologist's Point of View 6
Variant histologies in bladder cancer: Does the centre have an impact in detection accuracy? 6
Pd-l1 inhibitors for the treatment of prostate cancer 6
Contemporary grading of prostate cancer: 2017 update for pathologists and clinicians 6
Predictive and prognostic biomarkers in urological tumours 6
Clinical utility of checkpoint inhibitors against metastatic bladder cancer: overcoming challenges to find a way forward 6
Spectrum of incipient (or precursor) lesions in the mucosa of the seminal vesicles 6
Biphasic Tumors of the Urogenital Tract: Selected Topics 6
Staging and reporting of renal cell carcinomas 6
Phase II Study of Nivolumab and Salvage Nivolumab/Ipilimumab in Treatment-Naive Patients With Advanced Clear Cell Renal Cell Carcinoma (HCRN GU16-260-Cohort A) 6
Risk Classification of Bladder Cancer by Gene Expression and Molecular Subtype 6
T1 bladder carcinoma with variant histology: pathological features and clinical significance 6
From undergraduate medical school student to visible pathologist 5
Androgen Receptor Signaling Pathway in Prostate Cancer: From Genetics to Clinical Applications 5
Intraductal Carcinoma of the Prostate: Pathogenesis and Molecular Perspectives 5
Are liver nested stromal epithelial tumors always low aggressive? 5
Current application of the enhanced recovery after surgery protocol for patients undergoing radical cystectomy: lessons learned from European excellence centers 5
Immunotherapy in genitourinary cancers: Where are we going? 5
Correlation between high pd-l1 and emt/invasive genes expression and reduced recurrence-free survival in blood-circulating tumor cells from patients with non-muscle-invasive bladder cancer 5
Predicting biochemical recurrence after radical prostatectomy: the role of prognostic grade group and index tumor nodule 5
Molecular diagnostics in uro-oncology 5
Digital frozen section of the prostate surface during radical prostatectomy: a novel approach to evaluate surgical margins 5
Adjuvant immunotherapy in patients with renal cell carcinoma and urothelial carcinoma: A systematic review and network meta-analysis 5
Morphologic spectrum of the epithelial tumors of the male and female urethra 5
TNM staging towards a personalized approach in metastatic urothelial carcinoma: What will the future be like?-a narrative review 5
Designing novel immunocombinations in metastatic renal cell carcinoma 5
Tivozanib for the treatment of renal cell carcinoma 5
Re: Scott Wilkinson, Huihui Ye, Fatima Karzai, et al. Nascent Prostate Cancer Heterogeneity Drives Evolution and Resistance to Intense Hormonal Therapy. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2021.03.009: Focus on Intraductal Carcinoma of the Prostate 5
Immunotherapy for urothelial cancer: from the diagnostic pathologist’s point of view 5
Extramammary Paget disease of the penis closely mimicking the penile analogue of stratified mucin-producing intraepithelial lesion 5
Sequential or Concomitant Inhibition of Cyclin-Dependent Kinase 4/6 Before mTOR Pathway in Hormone-Positive HER2 Negative Breast Cancer: Biological Insights and Clinical Implications 5
Chromophobe Renal Cell Carcinoma Aggressiveness and Immuno-oncology Therapy: How to Distinguish the Good One from the Bad One 5
Recurrent KRAS mutations are early events in the development of papillary renal neoplasm with reverse polarity 5
An update on investigational therapies that target STAT3 for the treatment of cancer 5
The molecular characteristics of non‐clear cell renal cell carcinoma: What’s the story morning glory? 5
Combining radiotherapy with immunocheckpoint inhibitors or CAR-T in Renal Cell Carcinoma 5
Surgical checklist adherence across urology expertise levels impacts transurethral resection of bladder tumour quality indicators 5
Added Clinical Value of Whole-mount Histopathology of Radical Prostatectomy Specimens: A Collaborative Review 5
The 1996 European Urology Focus on Preneoplastic Lesions of the Prostate 5
Predicting future cancer burden in the United States by artificial neural networks 5
Specimen handling: radical and partial nephrectomy specimens 5
Metabolomic profiling in renal cell carcinoma patients: News and views 5
Clinical Actionability of the Genomic Landscape of Metastatic Castration Resistant Prostate Cancer 5
Targeted treatment of renal cell carcinoma 5
Body Mass Index in Patients Treated with Cabozantinib for Advanced Renal Cell Carcinoma: A New Prognostic Factor? 5
Clinicopathologic analysis of upper urinary tract carcinoma with variant histology 4
The identification of immunological biomarkers in kidney cancers 4
PreImplantation Factor immunohistochemical expression correlates with prostate cancer aggressiveness 4
Long Non-coding RNAs in prostate cancer with emphasis on second chromosome locus associated with prostate-1 expression 4
Contemporary best practice in the management of urothelial carcinomas of the renal pelvis and ureter 4
RAS genes in colorectal carcinoma: Pathogenesis, testing guidelines and treatment implications 4
Prostate cancer with cribriform morphology: diagnosis, aggressiveness, molecular pathology and possible relationships with intraductal carcinoma 4
Liquid biopsy in the clinical management of bladder cancer: current status and future developments 4
Hot topics in renal cancer pathology: implications for clinical management 4
Narrative review: Predicting future molecular and clinical profiles of prostate cancer in the United States 4
Grading of Chromophobe Renal Cell Carcinoma: Do We Need It? 4
Variants and new entities of bladder cancer 4
New prostate cancer targets for diagnosis, imaging, and therapy: Focus on prostate-specific membrane antigen 4
Considerations on current and future issues related to reproducibility and accuracy in prostate cancer grading 4
Germline and somatic mutations in prostate cancer: Focus on defective DNA repair, PARP inhibitors and immunotherapy 4
Combination therapy in advanced urothelial cancer: the role of PARP, HER-2 and mTOR inhibitors 4
Treating prostate cancer by antibody-drug conjugates 4
Activity of chemokines in prostate and renal tumors and their potential role as future therapeutic targets 4
An evaluation of current prostate cancer diagnostic approaches with emphasis on liquid biopsies and prostate cancer 4
The human microbiota and prostate cancer: Friend or foe? 4
Reply to Eoin Dinneen, Jon Oxley, and Greg Shaw's Letter to the Editor re: Bernardo Rocco, Luca Sarchi, Simone Assumma, et al. Digital Frozen Sections with Fluorescence Confocal Microscopy During Robot-assisted Radical Prostatectomy: Surgical Technique. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2021.03.021 4
Circulating tumor cells in renal cell carcinoma: Recent findings and future challenges 4
Predicting outcomes in non-muscle invasive (Ta/T1) bladder cancer: the role of molecular grade based on luminal/basal phenotype 4
Key role of obesity in genitourinary tumors with emphasis on urothelial and prostate cancers 4
Totale 664
Salva come PNG Salva come JPEG
Categoria #
all - tutte 16.550
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 16.550
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2022/2023628 0 0 0 0 0 0 1 2 512 9 60 44
2023/2024366 25 9 17 10 36 24 10 22 88 112 13 0
Totale 994